PIRAMAL PHARMA SOLUTIONS COMMEMORATES OPENING OF ITS ADC MANUFACTURING EXPANSION IN GRANGEMOUTH, SCOTLAND

Ribbon cutting and commissioning of a multipurpose state-of-the-art Antibody-Drug Conjugate (ADC) manufacturing facility that expands capacity by approximately 70-80%

Adrian Gillespie, Chief Executive of Scottish Enterprise, joins senior Piramal management team and site leadership to mark the occasion

The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant

MUMBAI, India and GRANGEMOUTH, Scotland, Dec. 18, 2023 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (PPL) (NSE: PPLPHARMA) (BSE: 543635), today celebrated the opening of its expanded antibody-drug conjugate (ADC) manufacturing facility in Grangemouth, Scotland, UK.

Continue Reading

Preview

来源: PRNewswire

Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions

Preview

来源: PRNewswire

Adrian Gillespie, Chief Executive of Scottish Enterprise

Preview

来源: PRNewswire

Wellbeing Economy Secretary Neil Gray

Preview

来源: PRNewswire

Ceremonial Ribbon Cutting, Piramal Pharma Solutions Grangemouth, Scotland Site Expansion. Left to right: Adrian Gillespie, Chief Executive of Scottish Enterprise; Herve Berdou, COO, Piramal Pharma Solutions; Francois Houbart, Managing Director and Grangemouth Site Head, Piramal Pharma Solutions; Nandini Piramal, Chairperson, Piramal Pharma Limited; Peter DeYoung, CEO, Piramal Pharma Solutions.

Preview

来源: PRNewswire

External view, Piramal Pharma Solutions Grangemouth, Scotland Site Expansion.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。